2024
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapy
2021
Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2018
Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S, Lafourcade B, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo J, Gessner B, Meda N, Borrow R, Trotter C, Mueller J. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Clinical Infectious Diseases 2018, 68: 435-443. PMID: 30481265, DOI: 10.1093/cid/ciy488.Peer-Reviewed Original ResearchConceptsPre-vaccination levelsAge groupsBooster campaignAntibody persistenceMeningococcal serogroup A conjugate vaccineSerum bactericidal antibody titersBactericidal antibody titersYounger age groupsOlder age groupsImmunoglobulin G concentrationCross-sectional surveyTime of returnDifferent age groupsConjugate vaccineAntibody titersImmune protectionGeneral populationMass vaccinationSerological surveyComplete returnOlder individualsMass campaignsBurkina FasoGeometric meanBobo-DioulassoPlasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina Faso
2017
TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO
Barry N, Kaboré N, Kabré Z, Fofana A, Nikèma F, Compaoré D, Somé F, Zongo I, Djimdé A, Ouédraogo J. TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO. BMJ Global Health 2017, 2: a24. DOI: 10.1136/bmjgh-2016-000260.62.Peer-Reviewed Original ResearchArtemether-lumefantrineUncomplicated malariaTreatment failurePA groupAL groupEffective malaria vaccineStandard of careNew therapeutic drugsPyronaridine-ArtesunateMalaria vaccinePatient groupTherapeutic failureFirst episodeTreatment responseDay 28Malaria diagnosisDay 42Burkina FasoMalaria controlEvidence baseLess casesPlasmodium sppTherapeutic drugsMalariaBobo-Dioulasso
2012
<i>Neisseria meningitis</i> serogroup X outbreak in Burkina Faso, 2009-2010
Yaro S, Drabo A, Ouangraoua S, Kirakoya-Samadoulougou F, Mueller J, Sanou O, Tall H, Jaillard P, Njanpop-Lafourcade B, Macq J, Robert A, Ouedraogo J. Neisseria meningitis serogroup X outbreak in Burkina Faso, 2009-2010. Open Journal Of Internal Medicine 2012, 2012: 41-49. DOI: 10.4236/ojim.2012.22010.Peer-Reviewed Original ResearchVaccine introductionPolymerase chain reactionSerogroup XPneumococcal vaccine introductionContacts of patientsReference laboratoryCountries' national guidelinesPilot districtsAdequate antibioticsCentre MurazCampaign vaccinationSecondary casesPolyvalent vaccineSerogroup distributionFluid collectionNational guidelinesVaccine compositionCSF samplesEpidemiological seasonFaster careLaboratory capacityAttack rateChain reactionBobo-DioulassoPatients
2009
Main characteristics of the street food sector in Bobo-Dioulasso, Burkina Faso.
Drabo K, Toe L, Savadogo L, Tarnagda Z, Zeba A, Zongo I, Rouamba J, Toe A, Ouédraogo D, Ouédraogo J. Main characteristics of the street food sector in Bobo-Dioulasso, Burkina Faso. Bulletin De La Société De Pathologie Exotique 2009, 102: 36-40. PMID: 19343919.Peer-Reviewed Original Research
2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
2006
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Dokomajilar C, Lankoande Z, Dorsey G, Zongo I, Ouedraogo J, Rosenthal P. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2006, 75: 162-5. PMID: 16837725, DOI: 10.4269/ajtmh.2006.75.162.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnimalsAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenes, MDRHumansMembrane ProteinsMembrane Transport ProteinsMutationPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineRecurrenceSulfadoxineTetrahydrofolate DehydrogenaseConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum mutationsPlasmodium falciparum malariaP. falciparum resistanceFalciparum malariaFalciparum resistanceNew infectionsAmodiaquineDhfr-164LBobo-DioulassoSignificant increaseBurkina FasoSame mutationTreatmentKey polymorphismsMutationsTarget genesTherapyInfectionMalariaPrevalenceRecrudescence
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, Rosenthal P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrials
2002
Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000
Tinto H, Zoungrana E, Coulibaly S, Ouedraogo J, Traoré M, Guiguemde T, Van Marck E, D'Alessandro U. Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000. Tropical Medicine And International Health 2002, 7: 925-930. PMID: 12390597, DOI: 10.1046/j.1365-3156.2002.00952.x.Peer-Reviewed Original ResearchConceptsPrevalence of anemiaClinical failureParasitological resistancePacked cell volumeUncomplicated malariaDay 14Day 0Uncomplicated malaria treatmentHaematological recoveryMalaria treatmentCQ resistanceHealth centersRegular surveillanceAntimalarial drugsChloroquineBurkina FasoPrevalenceBobo-DioulassoChildrenAnemiaEvidence of increasesMalariaTreatmentFailureCell volume
2001
In vitro susceptibility of 232 isolates of Plasmodium falciparum to antimalarials in Burkina Faso (West Africa).
Tinto H, Ouedraogo J, Traoré B, Coulibaly S, Guiguemde T. In vitro susceptibility of 232 isolates of Plasmodium falciparum to antimalarials in Burkina Faso (West Africa). Bulletin De La Société De Pathologie Exotique 2001, 94: 188-91. PMID: 16579075.Peer-Reviewed Original ResearchConceptsP. falciparumPlasmodium falciparumCells/mm3Chloroquine-resistant strainsInclusion criteriaReference centerParasite countsSingle infectionResistant isolatesSignificant positive correlationParasite growthPersistence of resistanceFalciparumHalofantrineBobo-DioulassoSignificant increaseMefloquineIC50 valuesPositive correlationIsolatesQuinineSusceptibilityPatientsBurkina FasoIncubation period
2000
The simplified isotopic microtest: a method for studying the drug resistance in vitro of Plasmodium falciparum to antimalarial drugs.
Tinto H, Ouédraogo J, Coulibaly S, Traoré B, Guiguemdé T. The simplified isotopic microtest: a method for studying the drug resistance in vitro of Plasmodium falciparum to antimalarial drugs. Cahiers De Santé 2000, 10: 353-6. PMID: 11125342.Peer-Reviewed Original Research
1998
In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa).
Ouédraogo J, Dutheil Y, Tinto H, Traoré B, Zampa H, Tall F, Coulibaly S, Guiguemdé T. In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Tropical Medicine And International Health 1998, 3: 381-4. PMID: 9623943.Peer-Reviewed Original ResearchConceptsChloroquine-resistant isolatesMean IC50 valuesChloroquine-sensitive isolatesDrug-resistant isolatesBobo-DioulassoIC50 valuesProportion of isolatesParasite densityMefloquineSignificant positive correlationHalofantrinePlasmodium falciparumNew antimalarialsCase of quinineSignificant differencesQuinineChloroquineAntimalarialsPositive correlationIsolatesBurkina FasoProportion
1997
Malaria morbidity in adults living in urban Burkina Faso.
Guiguemde T, Ouedraogo I, Ouedraogo J, Coulibaly S, Gbary A. Malaria morbidity in adults living in urban Burkina Faso. Medecine Tropicale 1997, 57: 165-8. PMID: 9304011.Peer-Reviewed Original ResearchConceptsLevel of immunizationPoor positive predictive valueSerious public health problemMain clinical featuresPublic health problemDiagnosis of malariaBobo-DioulassoPositive predictive valueParasitic indexMedian parasitemiaClinical featuresClinical symptomsMalaria morbidityProspective studyParasitological featuresParasite densityHigh incidencePlace of residencePredictive valueHealth problemsEndemic malariaMalariaUrban Burkina FasoAdultsMicroscopic examination
1994
Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991).
Guiguemde T, Aouba A, Ouedraogo J, Lamizana L. Ten-year surveillance of drug-resistant malaria in Burkina Faso (1982-1991). American Journal Of Tropical Medicine And Hygiene 1994, 50: 699-704. PMID: 8024062, DOI: 10.4269/ajtmh.1994.50.699.Peer-Reviewed Original ResearchConceptsTen-year surveillanceBobo-DioulassoDrug-resistant malariaDrug-resistant formsPrevalence of resistanceFirst caseChloroquine sensitivityVivo resistanceCases of resistanceMalaria transmissionBurkina FasoPlasmodium falciparumMefloquineHigh rateMalariaPyrimethamineChloroquineVitroVivoActive surveyLevel of resistancePrevalenceHousehold expenditure on malaria prevention and treatment for families in the town of Bobo-Dioulasso, Burkina Faso
Guiguemde T, Dao F, Curtis V, Traore A, Sondo B, Testa J, Ouedraogo J. Household expenditure on malaria prevention and treatment for families in the town of Bobo-Dioulasso, Burkina Faso. Transactions Of The Royal Society Of Tropical Medicine And Hygiene 1994, 88: 285-287. PMID: 7974661, DOI: 10.1016/0035-9203(94)90079-5.Peer-Reviewed Original ResearchConceptsMalaria preventionHealth agentsEpisodes of malariaBobo-DioulassoChemical prophylaxisMore episodesTransmission seasonBed netsDisease preventionCent of familiesGood healthModern drugsAverage total costMosquito coilsPreventionMonthsTreatmentBurkina FasoMonthly incomeTotal family incomeAverage monthly incomeMalariaFamily incomeOverall expenditureEpisodes
1992
Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies.
Guiguemde T, Toe A, Sadeler B, Gbary A, Ouedraogo J, Louboutin-Croc J. Variation of the parasite density of Plasmodium falciparum in asymptomatic carriers: consequences for malaria chemoresistance studies. Medecine Tropicale 1992, 52: 313-5. PMID: 1435194.Peer-Reviewed Original ResearchConceptsDay 4Parasite densityDay 0Plasmodium falciparumAsymptomatic peopleAsymptomatic carriersInclusion criteriaMalaria prevalenceStudy 16Drug absorptionPrimary school childrenParasitaemiaBobo-DioulassoNycthemeral variationsFurther studiesSignificant differencesChildrenSchool childrenVivo testsFalciparumNegativationChemosensitivityGreater numberPrevalenceChemoresistance